The purpose of this systemic review was to investigate the indications of anti-vascular endothelial growth factor (anti-VEGF) in the treatment of ocular diseases. For this, a comprehensive literature research was performed exploring the current use of anti-VEGF in a variety of retinal or anterior segment diseases and highlighting the visual outcome for these patients. The anti-VEGF therapy is now commonly used for a wide range of pathologies like age-related macular degeneration, retinal vein occlusion or diabetic retinopathy. Pathological processes such as abnormal neovascularization, ocular angiogenesis and macular edema which can greatly reduce visual acuity are now targeted by anti-VEGF treatment, having a major impact on vision.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712945 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab.
Front Med (Lausanne)
January 2025
Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.
Background: Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy.
View Article and Find Full Text PDFIntravitreal AAV-IKV Mediated Delivery of Decorin Inhibits Choroidal Neovascularization, Fibrosis, Inflammation and Elevates Autophagy.
Exp Eye Res
January 2025
Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111. Electronic address:
Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly. The exudative or wet form of AMD is caused by choroidal neovascularization (CNV) and subsequently a macular edema. Wet AMD can be effectively treated with anti-vascular endothelial growth factor (VEGF) therapies.
View Article and Find Full Text PDFAnti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.
Invest New Drugs
January 2025
Department of Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Background: Immune checkpoint inhibitors (ICIs) combined with anti-vascular endothelial growth factor (VEGF) have been the standard first-line treatment of hepatocellular carcinoma (HCC). However, the efficacy of this combination in post-line treatment is still unknown. This study aimed to evaluate the efficacy and safety of the combination of anti-PD-L1 envafolimab and novel humanized anti-VEGF suvemcitug as second-line treatment for patients with HCC.
View Article and Find Full Text PDFTherapeutic Dilemma of a Juxtapapillary Retinal Capillary Hemangioma.
Cureus
December 2024
Department of Ophthalmology and Visual Science, Ophthalmology Clinic, Hospital Universiti Sains Malaysia, Universiti Sains Malaysia, Kubang Kerian, MYS.
A juxtapapillary retinal capillary hemangioma (JRCH) is a rare vascular hamartoma located on the optic nerve head or adjacent region. While often associated with von Hippel-Lindau (VHL) disease, JRCHs can also occur as an isolated condition, presenting unique therapeutic challenges and risks of visual impairment. We report a case of a 50-year-old Malay gentleman with diabetes mellitus who presented with a non-progressive superior visual field defect in his left eye for three months.
View Article and Find Full Text PDFA systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy.
Health Technol Assess
January 2025
Centre for Reviews and Dissemination, University of York, York, UK.
Background: Non-proliferative and proliferative diabetic retinopathy are common complications of diabetes and a major cause of sight loss. Anti-vascular endothelial growth factor drugs represent a treatment option for people with diabetic retinopathy and are routinely used to treat various other eye conditions. However, anti-vascular endothelial growth factor drugs are expensive relative to current care options, and it is unclear whether this additional cost is justified when the immediate risk of vision loss is lower compared to patients with more aggressive ophthalmological conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!